Although the role of extracorporeal myoglobin removal in severe AKI in terms of improved kidney outcomes has yet to be confirmed in prospective clinical trials, it is nevertheless often used in clinical practice [8, 13, 16]. The gene discussed is MB; the disease is acute kidney injury.